SUBSCRIBE
SUBSCRIBE
News   Drug Development

ArQule, Inc. Presents Three Studies at American Association for Cancer Research 100th Annual Meeting 2009

April 20, 2009 | 
1 min read
WOBURN, Mass.--(BUSINESS WIRE)--ArQule, Inc. (NASDAQ: ARQL) today announced that the Company is presenting three studies at the AACR (American Association for Cancer Research) 100th Annual Meeting 2009, April 18-22, 2009 in Denver, Colorado.
Preclinical
MORE ON THIS TOPIC
Opportunity of winning. man sees a illuminated trophy door. vector
Cancer
Merck’s billion-dollar Kelun bet pays off as TROP2 improves survival in endometrial cancer
May 19, 2026
 · 
2 min read
 · 
Tristan Manalac
3D. rocket soaring. Different rockets fly high and stand out. different from others, concept startup idea, new generation, faster work better
Drug Development
Is Revolution ‘the next oncology titan’? Truist analysts make the case
May 18, 2026
 · 
3 min read
 · 
Heather McKenzie
Fashionable halftone collage. Concept of partnership, sponsorship,agreement, contract conclusion. Illustration for web banner, social media banner, business presentation, marketing material. Vector illustration
Deals
Regeneron, Parabilis set out to create new drug class in deal worth up to $2.3B
May 18, 2026
 · 
2 min read
 · 
Gabrielle Masson
Target, miss the target, target shooting, dart, correct decisions, bow and arrow, dart on target, hits and misses (3d illustration)
Cancer
Regeneron misses again as melanoma combo bows to Merck’s Keytruda in Phase 3
May 18, 2026
 · 
2 min read
 · 
Tristan Manalac